N. A. Colabufo et al. / Bioorg. Med. Chem. 16 (2008) 3732–3743
3743
13. Morschhauser, F.; Zinzani, P. L.; Burgess, M.; Sloots, L.;
Bouafia, F.; Dumontet, C. Leuk. Lymphoma 2007, 48,
708–715.
OH, D2O exchanged), 3.62 (s, 2H NCH2 naphthalene),
3.78–3.86 (m, 8H, NCH2CH2 isoquinoline 2 of CH3),
7.00–7.70 (m, 8H aromatic).
14. Planting, A. S.; Sonneveld, P.; van der Gaast, A.;
Sparreboom, A.; van der Burg, M. E.; Luyten, G. P.; de
Leeuw, K.; de Boer-Dennert, M.; Wissel, P. S.; Jewell, R.
C.; Paul, E. M.; Purvis, N. B.; Verweij, J. Cancer
Chemother. Pharmacol. 2005, 55, 91–99.
15. Sparreboom, A.; Plantings, A. S.; Jewell, R. C.; van der
Burg, M. E.; van der Gaast, A.; de Bruijn, P.; Loos, W. J.;
Nooter, K.; Chandler, L. H.; Paul, E. M.; Wissel, P. S.;
Verweij, J. Anticancer Drugs 1999, 10, 719–728.
16. Pusztai, L.; Wagner, P.; Ibrahim, N.; Rivera, E.; Theria-
ult, R.; Booser, D.; Symmans, F. W.; Wong, F.; Blu-
menschein, G.; Fleming, D. R.; Rouzier, R.; Boniface, G.;
Hortobagyi, G. N. Cancer 2005, 104, 682–691.
17. Walker, J.; Martin, C.; Callaghan, R. Eur. J. Cancer 2004,
40, 594–605.
7.5.6. 6,7-Dimethoxy-2-(6-methoxy-naphthalen-2-ylmethyl)
-1,2,3,4-tetrahydro-isoquinoline (7h). White solid, 4%
yield from column chromatography (CHCl3). Recrystal-
lized from MeOH/Et2O. Mp 232–236 ꢁC. Anal.
(C23H25NO3ÆHClÆ0.5H2O) C, H, N. UV–vis kmax
=
278 nm (PBS) e = 5310. ESI+/MS m/z 364 (ESI M++1,
43), 171 (M+ 100). 1H NMR: d 2.78–2.86 (m, 4H,
NCH2CH2 and NCH2 isoquinoline), 3.58 (s, 2H,
NCH2 naphthalene), 3.77–3.92 (m, 11H, 3 of CH3 and
NCH2CH2), 6.46–7.73 (m, 8H, aromatic).
7.6. Statistical analysis
18. Mistry, P.; Stewart, A. J.; Dangerfield, W.; Okiji, S.;
Liddle, C.; Bootle, D.; Plumb, J. A.; Templeton, D.;
Charlton, P. Cancer Res. 2001, 61, 749–758.
19. Fox, E.; Bates, S. E. Expert Rev. Anticancer Ther. 2007, 7,
447–459.
The EC50 values of the compounds reported in Tables 1
and 2 were determined by non-linear curve fitting utiliz-
ing the GraphPad Prism program.33
20. Azzariti, A.; Colabufo, N. A.; Berardi, F.; Porcelli, L.;
Niso, M.; Simone, M. G.; Perrone, R.; Paradiso, A. Mol.
Cancer Ther. 2006, 5, 1807–1816.
Supplementary data
21. Colabufo, N. A.; Berardi, F.; Cantore, M.; Perrone, M.
G.; Contino, M.; Inglese, C.; Niso, M.; Perrone, R.;
Azzariti, A.; Simone, G. M.; Porcelli, L.; Paradiso, A.
Bioorg. Med. Chem. 2008, 16, 362–373.
Supplementary data associated with this article can be
22. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.;
Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. S.
J. Pharmacol. Exper. Ther. 2001, 299, 620–628.
23. Higgins, C. F. Nature 2007, 446, 749–757.
24. Boumendjel, A.; Macalou, S.; Ahmed-Belkacem, A.;
Blanc, M.; Di Pietro, A. Bioorg. Med. Chem. 2007, 15,
2892–2897.
25. Perrone, R.; Berardi, F.; Colabufo, N. A.; Leopoldo, M.;
Tortorella, V. J. Med. Chem. 1999, 42, 490–496.
26. Bambal, R. B.; Hanzlik, R. P. Arch. Biochem. Biophys.
1996, 334, 59–66.
27. Leopoldo, M.; Lacivita, E.; De Giorgio, P.; Colabufo, N.
A.; Niso, M.; Berardi, F.; Perrone, R. J. Med. Chem. 2006,
49, 358–365.
28. Colabufo, N. A.; Berardi, F.; Perrone, R.; Rapposelli, S.;
Digiacomo, M.; Balsamo, A. J. Med. Chem. 2006, 49,
6607–6613.
References and notes
1. Longley, D. B.; Johnston, P. G. J. Phatol. 2005, 205, 275–292.
2. Altemberg, G. A. Curr. Med. Chem. 2004, 4, 53–62.
3. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. J. Nat.
Cancer Inst. 2000, 92, 1295–1302.
4. Thomas, H.; Coley, H. M. Cancer Control 2003, 10, 159–
165.
5. Nobili, S.; Landini, I.; Giglioni, B.; Mini, E. Curr. Drug
Target 2006, 7, 861–879.
6. Perez-Tomas, R. Curr. Med. Chem. 2006, 13, 1859–1876.
7. Teodori, E.; Dei, S.; Martelli, S.; Scapecchi, F.; Gualtieri,
F. Curr. Drug Targets 2006, 7, 893–909.
´
´
8. Safa, A. R. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 7187–
7191.
29. Rautio, J.; Humphreys, J. E.; Webster, L. O.;
Balakrishnan, A.; Keogh, J. P.; Kunta, J. R.; Serabjit-
Singh, J.; Polli, J. W. Drug Metab. Dispos. 2006, 3, 786–
792.
9. Nagaoka, R.; Iwasaki, T.; Rokutanda, N.; Takeshita, A.;
Koibuchi, Y.; Horiguchi, J.; Shimokawa, N.; Iino, Y.;
Morishita, Y.; Koibuchi, N. Endocrine 2006, 30,
261–268.
30. Kangas, L.; Gro¨nroos, M.; Nieminem, A. L. Med. Biol.
1984, 62, 338–343.
31. Taub, M. E.; Podila, L.; Almeida, I. Drug Metab. Dispos.
2005, 33, 1679–1687.
32. Colabufo, N. A.; Berardi, F.; Contino, M.; Niso, M.;
Abate, C.; Perrone, R.; Tortorella, V. Naunyn-Schmiede-
berg’s Arch. Pharmacol. 2004, 370, 106–113.
33. GraphPad Prism Software, version for Windows; Graph-
Pad Software, Inc.: San Diego, CA, 1998.
´
´
´
10. Baekelandt, M.; Lehne, G.; Trope, C. G.; Szanto, I.;
Gustavssson, B.; Kristensen, G. B. J. Clin. Oncol. 2001,
19, 2983–2993.
11. Minderman, H.; O’Loughlin, K. L.; Pendyala, L.; Baer,
M. R. Clin. Cancer Res. 2004, 10, 1826–1834.
12. Rago, R. P.; Einstein, A.; Lush, R.; Beer, T. M.; Ko, Y. J.;
Henner, W. D.; Bubley, G.; Merica, E. A.; Garg, V.; Ette,
E.; Harding, M. V.; Dalton, V. S. Cancer Chemother.
Pharmacol. 2003, 51, 297–305.